|
Volumn 45, Issue 6, 2006, Pages 783-784
|
Treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia - Anti-viral therapy vs rituximab [9]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALPHA INTERFERON;
ANTIVIRUS AGENT;
CD20 ANTIBODY;
CORTICOSTEROID;
CRYOGLOBULIN;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
ERYTHROPOIETIN;
FUROSEMIDE;
IRON;
PEGINTERFERON ALPHA2B;
RHEUMATOID FACTOR;
RIBAVIRIN;
RITUXIMAB;
ANEMIA;
CRYOGLOBULINEMIA;
DISEASE ASSOCIATION;
DISEASE SEVERITY;
DOSE RESPONSE;
DRUG BLOOD LEVEL;
DRUG DOSE REDUCTION;
DRUG DOSE REGIMEN;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERABILITY;
GLOMERULONEPHRITIS;
HEPATITIS C;
HEPATITIS C VIRUS;
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;
HUMAN;
IMMUNE DEFICIENCY;
LETTER;
LIVER BIOPSY;
LOW DRUG DOSE;
MONOTHERAPY;
NONHUMAN;
PRIORITY JOURNAL;
PROTEIN BLOOD LEVEL;
PROTEINURIA;
RELAPSE;
REMISSION;
SHORT COURSE THERAPY;
TREATMENT FAILURE;
VIRUS STRAIN;
ANTIBODIES, MONOCLONAL;
ANTIVIRAL AGENTS;
CRYOGLOBULINEMIA;
GLOMERULONEPHRITIS;
HEPATITIS C;
HUMANS;
|
EID: 33745623963
PISSN: 14620324
EISSN: 14620332
Source Type: Journal
DOI: 10.1093/rheumatology/kel134 Document Type: Letter |
Times cited : (4)
|
References (5)
|